News & Updates

Show Multimedia Only

Allergy history, chemotherapy linked to oxaliplatin hypersensitivity reactions

04 Feb 2025

In patients with colorectal cancer, a history of allergy, previous oxaliplatin exposure, and chemotherapy regimens appear to increase the risk of having oxaliplatin hypersensitivity reactions, results of a recent study have shown.

Allergy history, chemotherapy linked to oxaliplatin hypersensitivity reactions

04 Feb 2025

SG study underpins novel Tx strategies for OCCC

04 Feb 2025 by

A study from Singapore shows that targeted therapies such as bevacizumab, immune checkpoint inhibitors (ICIs), and secondary cytoreductive surgery (SCS) hold promise for the treatment of ovarian clear cell carcinoma (OCCC).

SG study underpins novel Tx strategies for OCCC

04 Feb 2025

Original New Drug Application Approvals by US FDA (16-31 January 2025)

04 Feb 2025

New drug applications approved by US FDA as of 16-31 January 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 January 2025)

04 Feb 2025

Add-on tiragolumab improves antitumour response in unresectable HCC

03 Feb 2025

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), the addition of tiragolumab to atezolizumab plus bevacizumab yields meaningful improvements in antitumour response and disease control, according to data from an open-label phase 1b–2 study.

Add-on tiragolumab improves antitumour response in unresectable HCC

03 Feb 2025

Clozapine tied to haematological malignancy in schizophrenia

01 Feb 2025 by

The use of clozapine appears to slightly increase the risk of haematological malignancy (HM) among patients with schizophrenia compared with olanzapine use, suggests a study.

Clozapine tied to haematological malignancy in schizophrenia

01 Feb 2025

Laparoscopic noninferior to open surgery for low rectal cancer

01 Feb 2025

The disease-free survival outcome in patients with low rectal cancer who receive laparoscopic surgery compares favourably with that in those who receive open surgery, according to a study.

Laparoscopic noninferior to open surgery for low rectal cancer

01 Feb 2025

Pembrolizumab–bevacizumab combo works against nasopharyngeal carcinoma

29 Jan 2025

The combination of pembrolizumab plus bevacizumab shows promising activity against platinum-resistant nasopharyngeal carcinoma while having manageable toxicities, according to an open-label phase II study conducted in Singapore.